Pharmacokinetic/pharmacodynamic evaluation of multidose oritavancin for prolonged durations of therapy
- 1University of Wisconsin, Madison – School of Pharmacy, Madison, Wisconsin, USA
- 2State University of New York, Binghamton School of Pharmacy and Pharmaceutical Sciences, Binghamton, New York, USA
- 3State University of New York, Upstate Medical University, Syracuse, New York, USA
Abstract
Managing multidrug-resistant gram-positive infections is challenging, especially when prolonged therapy is needed for conditions like bacteremia, endocarditis, osteomyelitis, or other deep-seated infections. Oritavancin, a long-acting lipoglycopeptide, is increasingly used in these scenarios and offers an alternative to central catheter placement. However, despite its growing use for extended treatment, optimal dosing strategies and pharmacokinetic targets remain unclear. An in silico pharmacokinetic/pharmacodynamic simulation was performed to assess the predicted oritavancin concentration resulting from weekly and every 2-week dosing regimens. The simulations utilized a previously published model, which utilized pharmacokinetic sampling data from two single-dose, phase 3 clinical trials. A 100% free time above the MIC was utilized as the pharmacodynamic target. The Clinical and Laboratory Standards Institute breakpoint (0.12 µg/mL) and MIC90 (0.06 µg/mL) values for both Staphylococcus aureus and Enterococcus faecalis were utilized as benchmarks. Eighty-five percent protein binding was assumed. A six-dose regimen of 1,200 mg weekly is expected to maintain free plasma concentrations above the breakpoint for a median of 10.4 weeks (lower 5th percentile 9.6) and above the MIC90 for about 1.5 weeks longer, exceeding what is usually required for acute treatment of most infections. Alternatively, using a three-dose regimen of 1,200 mg every 2 weeks is expected to maintain free plasma concentrations above the breakpoint for a median of 8.4 weeks (lower 5th percentile 7.9), with trough values remaining therapeutic between doses. Every 2-week dosing strategies are expected to maintain therapeutic concentrations between doses. This strategy may be employed to reduce the cost of treatment and improve patient convenience.
Related
- Caenorhabditis elegans as a Model to Dissect Pharmacokinetic and Pharmacodynamic Relationships of Gabapentinoids
- Linking formulation composition to pharmacokinetic and pharmacodynamic responses: a predictive framework for sustained-release tablets
- Pharmacokinetic and pharmacodynamic strategies to optimize antifungal therapy, prevent resistance and minimize treatment failure
- Mapping the subcellular pharmacokinetic-pharmacodynamic landscape: a systems-pharmacology framework for predicting combination therapies against intracellular bacterial infections
- A novel meropenem dosing strategy for Outpatient Parenteral Antimicrobial Therapy (OPAT): a pilot pharmacokinetic/pharmacodynamic study in non-critically ill patients
BibTeX
@article{volk2026pharmacokineticpharmacodynamic,
title = {{Pharmacokinetic/pharmacodynamic evaluation of multidose oritavancin for prolonged durations of therapy}},
author = {Cecilia F. Volk and Max Blumenthal and Nolan Thomas and Wesley D. Kufel and Warren E. Rose and Sin Yin Lim},
journal = {Antimicrobial Agents and Chemotherapy},
year = {2026},
month = oct,
doi = {10.1128/aac.01049-26},
url = {https://doi.org/10.1128/aac.01049-26},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Pharmacokinetic/pharmacodynamic evaluation of multidose oritavancin for prolonged durations of therapy
AU - Cecilia F. Volk
AU - Max Blumenthal
AU - Nolan Thomas
AU - Wesley D. Kufel
AU - Warren E. Rose
AU - Sin Yin Lim
PY - 2026
DA - 2026/10/14
JO - Antimicrobial Agents and Chemotherapy
DO - 10.1128/aac.01049-26
UR - https://doi.org/10.1128/aac.01049-26
AB - Managing multidrug-resistant gram-positive infections is challenging, especially when prolonged therapy is needed for conditions like bacteremia, endocarditis, osteomyelitis, or other deep-seated infections. Oritavancin, a long-acting lipoglycopeptide, is increasingly used in these scenarios and offers an alternative to central catheter placement. However, despite its growing use for extended treatment, optimal dosing strategies and pharmacokinetic targets remain unclear. An in silico pharmacokinetic/pharmacodynamic simulation was performed to assess the predicted oritavancin concentration resulting from weekly and every 2-week dosing regimens. The simulations utilized a previously published model, which utilized pharmacokinetic sampling data from two single-dose, phase 3 clinical trials. A 100% free time above the MIC was utilized as the pharmacodynamic target. The Clinical and Laboratory Standards Institute breakpoint (0.12 µg/mL) and MIC90 (0.06 µg/mL) values for both Staphylococcus aureus and Enterococcus faecalis were utilized as benchmarks. Eighty-five percent protein binding was assumed. A six-dose regimen of 1,200 mg weekly is expected to maintain free plasma concentrations above the breakpoint for a median of 10.4 weeks (lower 5th percentile 9.6) and above the MIC90 for about 1.5 weeks longer, exceeding what is usually required for acute treatment of most infections. Alternatively, using a three-dose regimen of 1,200 mg every 2 weeks is expected to maintain free plasma concentrations above the breakpoint for a median of 8.4 weeks (lower 5th percentile 7.9), with trough values remaining therapeutic between doses. Every 2-week dosing strategies are expected to maintain therapeutic concentrations between doses. This strategy may be employed to reduce the cost of treatment and improve patient convenience.
SN - 1098-6596
SN - 0066-4804
ER -